Key result
Atrial fibrillation is linked to ~3.5-fold higher odds of critical outcomes or death in COVID-19.
Why the study?
Predictors of critical outcomes, including mortality, in hospitalized COVID-19 patients treated with remdesivir needed to be identified using statistical, machine learning, and Bayesian methods.
Does atrial fibrillation predict critical outcomes or death in hospitalized COVID-19 patients treated with remdesivir?
Cohort (n=1,628)
Yes
Does atrial fibrillation predict critical outcomes or death in hospitalized COVID-19 patients treated with remdesivir?
Atrial fibrillation is a significant, independent predictor of severe disease progression and mortality in hospitalized COVID-19 patients, underscoring its utility in early clinical risk stratification.
AF may inform risk stratification in remdesivir-treated COVID-19 inpatients; leaves open causal role and need for prospective validation.
This study aimed to identify predictors of critical outcomes, including mortality, in hospitalized COVID-19 patients treated with remdesivir, using statistical, machine learning, and Bayesian methods. A retrospective multicenter cohort of 1628 patients hospitalized between January 2021 and August 2022 was analyzed. Clinical data were collected from electronic medical records. Multivariable logistic regression, machine learning models (LightGBM, Elastic Net) with SHapley Additive exPlanations (SHAP), and Bayesian logistic regression were applied. Among the cohort, 14.5% experienced critical outcomes or death. Advanced age (≥ 65 years; aOR 3.950), atrial fibrillation (aOR 4.087), and kidney disease (aOR 1.939) were identified as significant predictors. Machine learning models achieved moderate predictive performance (AUROC: LightGBM 0.705, Elastic Net 0.698), with SHAP highlighting atrial fibrillation and age as key contributors. Bayesian analysis confirmed a strong association between atrial fibrillation and adverse outcomes (adjusted OR 5.121). Atrial fibrillation emerged as a consistent and strong predictor, underscoring its relevance in clinical risk assessment.
No takes yet. Share an insight, caveat, or question.
Ku et al. (2025) conducted a cohort in COVID-19 (n=1,628). Atrial fibrillation vs. No atrial fibrillation was evaluated on Critical outcomes or death (Adjusted OR 3.483, 95% CI 1.600-7.563, p=<0.05). Atrial fibrillation was identified as a strong independent predictor of critical outcomes or death in hospitalized COVID-19 patients treated with remdesivir (adjusted OR 3.483, 95% CI 1.600-7.563).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: